Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Ishares Diversified Alternatives Trust Charts. Click Here for more Ishares Diversified Alternatives Trust Charts.](/p.php?pid=staticchart&s=A%5EALT&p=8&t=15)
Alteon To Present at The BIO CEO & Investor Conference 2005
- Presentation to be Webcast -
PARSIPPANY, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT)
announced today that Kenneth I. Moch, President & Chief Executive Officer, will
present at the BIO CEO & Investor Conference, Wednesday, February 23, 2005,
3:30 pm, ET, at The Waldorf-Astoria, New York, NY.
Mr. Moch will discuss the clinical objectives for the ongoing Phase 2 programs
of alagebrium in systolic hypertension, heart failure and erectile dysfunction,
as well as provide an update of 2005 milestones. The presentation will be
webcast and can be viewed at the investor relations section of Alteon's
website, http://www.alteon.com/. It will be archived there after the event.
Note to BIO attendees: Alteon will be available for one-on-one meetings.
Please arrange through BIO or by calling Susan Pietropaolo at 201-818-5537.
About Alteon
Alteon is developing several new classes of drugs that have shown the potential
to reverse or slow down diseases of aging and complications of diabetes. These
compounds appear to have an impact on a fundamental pathological process caused
by the progressive formation of protein-glucose complexes called Advanced
Glycation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s
lead to a loss of flexibility and function in body tissues and organs and have
been shown to be a causative factor in many age- related diseases and diabetic
complications. Alteon has created a library of novel classes of compounds
targeting the A.G.E. pathway.
Alteon's lead compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has demonstrated safety and
efficacy in several Phase 2 trials and is actively being developed for systolic
hypertension, heart failure and erectile dysfunction. Over 1200 patients have
been involved in alagebrium's human clinical trials to date, of whom
approximately 900 have received active compound. Ongoing clinical trials
include the Phase 2b systolic hypertension trial, SPECTRA (Systolic Pressure
Efficacy and Safety Trial of Alagebrium), the Phase 2a heart failure trial,
PEDESTAL (Patients with Impaired Ejection Fraction and Diastolic Dysfunction:
Efficacy and Safety Trial of ALagebrium), the Phase 2a trial EMERALD
(Evaluation of Alagebrium in Erectile Dysfunction in Diabetic Males on PDE5
Inhibitors), as well as a fourth trial exploring mechanism of action in
endothelial dysfunction. For more detailed information about alagebrium,
please visit the scientific publications section of the Alteon website,
http://www.alteon.com/.
Any statements contained in this press release that relate to future plans,
events or performance are forward-looking statements that involve risks and
uncertainties including, but not limited to, those relating to technology and
product development (including the possibility that early clinical trial
results may not be predictive of results that will be obtained in large-scale
testing or that any clinical trials will not demonstrate sufficient safety and
efficacy to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property rights and
litigation, competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange Commission. The
information contained in this press release is accurate as of the date
indicated. Actual results, events or performance may differ materially. Alteon
undertakes no obligation to publicly release the result of any revision to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
DATASOURCE: Alteon Inc.
CONTACT: Susan M. Pietropaolo, Director, Corporate Communications &
Investor Relations, +1-201-818-5537,
Web site: http://www.alteonpharma.com/